Thyroid transcription factor 1 - a new prognostic factor in lung cancer: a meta-analysis
Thyroid transcription factor 1 - a new prognostic factor in lung cancer: a meta-analysis
复制标题
DOI：
10.1093/annonc/mdl287
复制
发表时间：
2006-11-01
影响因子：
50.5
通讯作者：
Sculier, J. -P.
中科院分区：
文献类型：
--
作者：
Berghmans, T.;Paesmans, M.;Sculier, J. -P.
背景：本研究旨在确定甲状腺转录因子1（TTF - 1）在肺癌生存中的预后作用。
方法：采用一种方法学评分系统对2005年8月前发表的评估肺癌患者生存情况和TTF - 1的研究进行评估。从这些出版物中提取用于估计个体生存风险比（HRs）所需的数据，并计算综合风险比。
结果：我们确定了10篇符合条件的论文，均涉及非小细胞肺癌（NSCLC）。对其中8篇进行了荟萃分析（可评估的研究）。7项研究纳入了局部和/或局部区域疾病患者，3项仅涉及腺癌。方法学质量评分中位数为65.9%（范围 = 31.8% - 70.5%）。在1项和4项研究中，TTF - 1阳性分别与具有统计学意义的生存降低和提高相关。8项可评估研究的综合风险比为0.64[95%置信区间（CI）= 0.41 - 1.00]。在腺癌亚组中，综合风险比为0.53（95% CI = 0.29 - 0.95）。
结论：TTF - 1是NSCLC生存的一个良好预后因素。当分析仅限于腺癌患者时，其作用似乎也很显著。本研究支持将TTF - 1纳入进一步研究NSCLC预后因素的前瞻性试验这一事实。
Background: The aim of this study was to determine the prognostic role for survival of thyroid transcription factor 1 (TTF-1) in lung cancer.Methods: Studies evaluating survival and TTF-1 in lung cancer patients, published until August 2005, were assessed with a methodological scoring system. The required data for estimation of individual hazard ratios (HRs) for survival were extracted from the publications and a combined HR was calculated.Results: We identified 10 eligible papers, all dealing with non-small-cell lung cancer (NSCLC). Eight were meta-analysed (evaluable studies). Seven studies included patients with local and/or locoregional diseases and three dealt only with adenocarcinoma. Median methodological quality score was 65.9% (range = 31.8%-70.5%). TTF-1 positivity was associated with statistically significant reduced or improved survival in one and four studies, respectively. Combined HR for the eight evaluable studies was 0.64 [95% confidence interval (CI) = 0.41-1.00]. In the subgroup of adenocarcinoma, the combined HR was 0.53 (95% CI = 0.29-0.95).Conclusion: TTF-1 is a good prognostic factor for survival in NSCLC. Its effect appears also significant when the analysis is restricted to patients with adenocarcinoma. This study supports the fact that TTF-1 could be included in further prospective trials studying prognostic factors in NSCLC.